{
  "analysis_mode": "HISTORICAL_ONLY",
  "report_version": "5.0",
  "symbol": "SVNS.L",
  "generated_at": "2026-01-29T13:23:35.512989+00:00",
  "comprehensive_apex": {
    "score": 43,
    "rating": "MODERATE",
    "color": "#f59e0b",
    "calculation": "(61\u00d725% + 45\u00d720% + 50.5\u00d730% + 32\u00d725%) \u00d7 0.9 = 43",
    "components": {
      "setup": {
        "score": 61,
        "weight": 0.25
      },
      "trust": {
        "score": 45,
        "weight": 0.2
      },
      "panic": {
        "score": 50.5,
        "weight": 0.3
      },
      "compression": {
        "score": 32,
        "weight": 0.25
      }
    },
    "timing": {
      "regime": "EARLY_BUILD",
      "multiplier": 0.9
    }
  },
  "top_card": {
    "ticker": "SVNS.L",
    "company_name": "Solvonis Therapeutics plc",
    "sector": "Industrials",
    "market_cap_gbp": 18139065,
    "days_active": 325,
    "apex_score_100": 61,
    "confidence_score_100": 45,
    "panic_score_100": 50.5,
    "cc_score_100": 32,
    "ai_final_score_25": 15,
    "ai_strength": "STRONG",
    "timing_regime": "EARLY_BUILD",
    "action": "WATCH",
    "thesis_one_liner": "WATCH - EARLY_BUILD timing with 61/100 opportunity score",
    "overall_score_100": 47
  },
  "enrichment": {
    "company_info": {
      "name": "Solvonis Therapeutics plc",
      "sector": "Industrials",
      "industry": "Specialty Industrial Machinery",
      "exchange": "LSE",
      "market": "MAIN",
      "currency": "GBP",
      "risk_tier": "Low Risk",
      "current_market_cap": 18139065,
      "current_close_price": 0.2665
    },
    "basics": {
      "ticker": "SVNS.L",
      "current_price": 0.2665,
      "ath": 22.463,
      "atl": 0.1,
      "ath_date": "2022-01-06",
      "atl_date": "2024-03-15",
      "week_52_high": 0.4,
      "week_52_low": 0.11,
      "week_52_high_date": "2025-10-07",
      "week_52_low_date": "2025-04-17",
      "drawdown_from_ath_pct": 98.81,
      "data_start": "2022-01-06",
      "data_end": "2026-01-29",
      "total_bars": 859
    },
    "latest_signal": {
      "date": "2025-03-10",
      "scan_date": "2026-01-26",
      "signal_type": "DEEP CRASH BOTTOM",
      "signal_color": "GREEN",
      "price": 0.155,
      "drawdown_pct": 88.98,
      "ai_score": 12.0,
      "rsi": 20.0,
      "cycle_position": 0.0505,
      "holding_period_days": 325,
      "current_pnl_pct": 71.94,
      "rally_state": "pulling_back",
      "distance_from_high_pct": -29.74,
      "Rally_Count": 3,
      "days_since_last_high": 19,
      "last_high_date": "2026-01-07",
      "lock_in_reached": true,
      "lock_in_date": "2025-10-07",
      "best_rally_pct": 151.61
    },
    "best_historical_signal": {
      "signal_date": "2024-04-08",
      "signal_type": "EXTREME CRASH BOTTOM",
      "signal_color": "ORANGE",
      "entry_price": 0.135,
      "peak_price": 1.407,
      "peak_date": "2024-05-31",
      "rally_pct": 942.22,
      "days_to_peak": 53,
      "ai_score": 13.0
    },
    "all_historical_signals": [
      {
        "signal_id": "SVNS.L_2023-09-27",
        "signal_date": "2023-09-27",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 1.7,
        "current_price": 0.274,
        "current_return_pct": -83.88,
        "best_rally_pct": 8.82,
        "best_rally_date": "2023-10-09",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": -85.19,
        "days_since_last_high": 19,
        "lock_in_reached": true,
        "age_days": 852,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2023-09-28",
        "signal_date": "2023-09-28",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 1.65,
        "current_price": 0.274,
        "current_return_pct": -83.39,
        "best_rally_pct": 12.12,
        "best_rally_date": "2023-10-09",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -85.19,
        "days_since_last_high": 19,
        "lock_in_reached": true,
        "age_days": 851,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2023-11-16",
        "signal_date": "2023-11-16",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 1.4,
        "current_price": 0.274,
        "current_return_pct": -80.43,
        "best_rally_pct": -0.0,
        "best_rally_date": "2023-11-17",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": 0.0,
        "days_since_last_high": 19,
        "lock_in_reached": true,
        "age_days": 802,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2023-11-23",
        "signal_date": "2023-11-23",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 1.3,
        "current_price": 0.274,
        "current_return_pct": -78.92,
        "best_rally_pct": -3.85,
        "best_rally_date": "2023-11-24",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": 0.0,
        "days_since_last_high": 19,
        "lock_in_reached": true,
        "age_days": 795,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2023-11-24",
        "signal_date": "2023-11-24",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 1.25,
        "current_price": 0.274,
        "current_return_pct": -78.08,
        "best_rally_pct": 0.0,
        "best_rally_date": "2023-11-27",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": 0.0,
        "days_since_last_high": 19,
        "lock_in_reached": true,
        "age_days": 794,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2023-11-29",
        "signal_date": "2023-11-29",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 1.05,
        "current_price": 0.274,
        "current_return_pct": -73.9,
        "best_rally_pct": -0.0,
        "best_rally_date": "2023-11-30",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": 0.0,
        "days_since_last_high": 19,
        "lock_in_reached": true,
        "age_days": 789,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2023-11-30",
        "signal_date": "2023-11-30",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 1.05,
        "current_price": 0.274,
        "current_return_pct": -73.9,
        "best_rally_pct": -0.0,
        "best_rally_date": "2023-12-01",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": 0.0,
        "days_since_last_high": 19,
        "lock_in_reached": true,
        "age_days": 788,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2023-12-12",
        "signal_date": "2023-12-12",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 1.0,
        "current_price": 0.274,
        "current_return_pct": -72.6,
        "best_rally_pct": 1.0,
        "best_rally_date": "2024-05-31",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": -72.87,
        "days_since_last_high": 19,
        "lock_in_reached": true,
        "age_days": 776,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2023-12-19",
        "signal_date": "2023-12-19",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 1.0,
        "current_price": 0.274,
        "current_return_pct": -72.6,
        "best_rally_pct": 1.0,
        "best_rally_date": "2024-05-31",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": -72.87,
        "days_since_last_high": 19,
        "lock_in_reached": true,
        "age_days": 769,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2023-12-22",
        "signal_date": "2023-12-22",
        "signal_type": "ULTRA CRASH BOTTOM",
        "signal_color": "RED",
        "entry_price": 0.725,
        "current_price": 0.274,
        "current_return_pct": -62.21,
        "best_rally_pct": 39.31,
        "best_rally_date": "2024-05-31",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -72.87,
        "days_since_last_high": 19,
        "lock_in_reached": true,
        "age_days": 766,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2023-12-28",
        "signal_date": "2023-12-28",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.66,
        "current_price": 0.274,
        "current_return_pct": -58.48,
        "best_rally_pct": 53.03,
        "best_rally_date": "2024-05-31",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -72.87,
        "days_since_last_high": 19,
        "lock_in_reached": true,
        "age_days": 760,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2023-12-29",
        "signal_date": "2023-12-29",
        "signal_type": "ULTRA CRASH BOTTOM",
        "signal_color": "RED",
        "entry_price": 0.575,
        "current_price": 0.274,
        "current_return_pct": -52.35,
        "best_rally_pct": 75.65,
        "best_rally_date": "2024-05-31",
        "rally_state": "accumulating",
        "Rally_Count": 3,
        "distance_from_high_pct": -72.87,
        "days_since_last_high": 19,
        "lock_in_reached": true,
        "age_days": 759,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2024-01-02",
        "signal_date": "2024-01-02",
        "signal_type": "ULTRA CRASH BOTTOM",
        "signal_color": "RED",
        "entry_price": 0.575,
        "current_price": 0.274,
        "current_return_pct": -52.35,
        "best_rally_pct": 75.65,
        "best_rally_date": "2024-05-31",
        "rally_state": "accumulating",
        "Rally_Count": 3,
        "distance_from_high_pct": -72.87,
        "days_since_last_high": 19,
        "lock_in_reached": true,
        "age_days": 755,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2024-01-03",
        "signal_date": "2024-01-03",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 0.65,
        "current_price": 0.274,
        "current_return_pct": -57.85,
        "best_rally_pct": 55.38,
        "best_rally_date": "2024-05-31",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -72.87,
        "days_since_last_high": 19,
        "lock_in_reached": true,
        "age_days": 754,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2024-03-04",
        "signal_date": "2024-03-04",
        "signal_type": "ULTRA CRASH BOTTOM",
        "signal_color": "RED",
        "entry_price": 0.65,
        "current_price": 0.274,
        "current_return_pct": -57.85,
        "best_rally_pct": 55.38,
        "best_rally_date": "2024-05-31",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -72.87,
        "days_since_last_high": 19,
        "lock_in_reached": true,
        "age_days": 693,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2024-03-05",
        "signal_date": "2024-03-05",
        "signal_type": "ENHANCED DEEP CRASH-ACCUM COMBO",
        "signal_color": "PURPLE",
        "entry_price": 0.65,
        "current_price": 0.274,
        "current_return_pct": -57.85,
        "best_rally_pct": 55.38,
        "best_rally_date": "2024-05-31",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -72.87,
        "days_since_last_high": 19,
        "lock_in_reached": true,
        "age_days": 692,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2024-03-06",
        "signal_date": "2024-03-06",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 0.525,
        "current_price": 0.274,
        "current_return_pct": -47.81,
        "best_rally_pct": 92.38,
        "best_rally_date": "2024-05-31",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -72.87,
        "days_since_last_high": 19,
        "lock_in_reached": true,
        "age_days": 691,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2024-03-08",
        "signal_date": "2024-03-08",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.525,
        "current_price": 0.274,
        "current_return_pct": -47.81,
        "best_rally_pct": 92.38,
        "best_rally_date": "2024-05-31",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -72.87,
        "days_since_last_high": 19,
        "lock_in_reached": true,
        "age_days": 689,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2024-03-15",
        "signal_date": "2024-03-15",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 0.25,
        "current_price": 0.274,
        "current_return_pct": 9.6,
        "best_rally_pct": 304.0,
        "best_rally_date": "2024-05-31",
        "rally_state": "pulling_back",
        "Rally_Count": 7,
        "distance_from_high_pct": -72.87,
        "days_since_last_high": 19,
        "lock_in_reached": true,
        "age_days": 682,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2024-03-18",
        "signal_date": "2024-03-18",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 0.275,
        "current_price": 0.274,
        "current_return_pct": -0.36,
        "best_rally_pct": 267.27,
        "best_rally_date": "2024-05-31",
        "rally_state": "accumulating",
        "Rally_Count": 4,
        "distance_from_high_pct": -72.87,
        "days_since_last_high": 19,
        "lock_in_reached": true,
        "age_days": 679,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2024-04-08",
        "signal_date": "2024-04-08",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.135,
        "current_price": 0.274,
        "current_return_pct": 102.96,
        "best_rally_pct": 648.15,
        "best_rally_date": "2024-05-31",
        "rally_state": "pulling_back",
        "Rally_Count": 7,
        "distance_from_high_pct": -72.87,
        "days_since_last_high": 19,
        "lock_in_reached": true,
        "age_days": 658,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2024-04-09",
        "signal_date": "2024-04-09",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.135,
        "current_price": 0.274,
        "current_return_pct": 102.96,
        "best_rally_pct": 648.15,
        "best_rally_date": "2024-05-31",
        "rally_state": "pulling_back",
        "Rally_Count": 7,
        "distance_from_high_pct": -72.87,
        "days_since_last_high": 19,
        "lock_in_reached": true,
        "age_days": 657,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2024-07-03",
        "signal_date": "2024-07-03",
        "signal_type": "ULTRA CRASH BOTTOM",
        "signal_color": "RED",
        "entry_price": 0.135,
        "current_price": 0.274,
        "current_return_pct": 102.96,
        "best_rally_pct": 188.89,
        "best_rally_date": "2025-10-07",
        "rally_state": "pulling_back",
        "Rally_Count": 5,
        "distance_from_high_pct": -29.74,
        "days_since_last_high": 19,
        "lock_in_reached": true,
        "age_days": 572,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2024-07-04",
        "signal_date": "2024-07-04",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.135,
        "current_price": 0.274,
        "current_return_pct": 102.96,
        "best_rally_pct": 188.89,
        "best_rally_date": "2025-10-07",
        "rally_state": "pulling_back",
        "Rally_Count": 5,
        "distance_from_high_pct": -29.74,
        "days_since_last_high": 19,
        "lock_in_reached": true,
        "age_days": 571,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2024-07-05",
        "signal_date": "2024-07-05",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.115,
        "current_price": 0.274,
        "current_return_pct": 138.26,
        "best_rally_pct": 239.13,
        "best_rally_date": "2025-10-07",
        "rally_state": "pulling_back",
        "Rally_Count": 1,
        "distance_from_high_pct": -29.74,
        "days_since_last_high": 19,
        "lock_in_reached": true,
        "age_days": 570,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2024-07-09",
        "signal_date": "2024-07-09",
        "signal_type": "ULTRA CRASH BOTTOM",
        "signal_color": "RED",
        "entry_price": 0.123,
        "current_price": 0.274,
        "current_return_pct": 122.76,
        "best_rally_pct": 217.07,
        "best_rally_date": "2025-10-07",
        "rally_state": "pulling_back",
        "Rally_Count": 2,
        "distance_from_high_pct": -29.74,
        "days_since_last_high": 19,
        "lock_in_reached": true,
        "age_days": 566,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2024-07-10",
        "signal_date": "2024-07-10",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.143,
        "current_price": 0.274,
        "current_return_pct": 91.61,
        "best_rally_pct": 172.73,
        "best_rally_date": "2025-10-07",
        "rally_state": "pulling_back",
        "Rally_Count": 5,
        "distance_from_high_pct": -29.74,
        "days_since_last_high": 19,
        "lock_in_reached": true,
        "age_days": 565,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2024-07-11",
        "signal_date": "2024-07-11",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 0.205,
        "current_price": 0.274,
        "current_return_pct": 33.66,
        "best_rally_pct": 90.24,
        "best_rally_date": "2025-10-07",
        "rally_state": "pulling_back",
        "Rally_Count": 5,
        "distance_from_high_pct": -29.74,
        "days_since_last_high": 19,
        "lock_in_reached": true,
        "age_days": 564,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2024-07-18",
        "signal_date": "2024-07-18",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 0.19,
        "current_price": 0.274,
        "current_return_pct": 44.21,
        "best_rally_pct": 105.26,
        "best_rally_date": "2025-10-07",
        "rally_state": "pulling_back",
        "Rally_Count": 6,
        "distance_from_high_pct": -29.74,
        "days_since_last_high": 19,
        "lock_in_reached": true,
        "age_days": 557,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2024-09-05",
        "signal_date": "2024-09-05",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 0.153,
        "current_price": 0.274,
        "current_return_pct": 79.08,
        "best_rally_pct": 154.9,
        "best_rally_date": "2025-10-07",
        "rally_state": "pulling_back",
        "Rally_Count": 5,
        "distance_from_high_pct": -29.74,
        "days_since_last_high": 19,
        "lock_in_reached": true,
        "age_days": 508,
        "status": "historical"
      },
      {
        "signal_id": "SVNS.L_2025-03-10",
        "signal_date": "2025-03-10",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 0.155,
        "current_price": 0.274,
        "current_return_pct": 76.77,
        "best_rally_pct": 151.61,
        "best_rally_date": "2025-10-07",
        "rally_state": "pulling_back",
        "Rally_Count": 3,
        "distance_from_high_pct": -29.74,
        "days_since_last_high": 19,
        "lock_in_reached": true,
        "age_days": 322,
        "status": "historical"
      }
    ],
    "stats": {
      "total_signals": 31,
      "win_rate_pct": 100.0,
      "avg_rally_pct": 185.22,
      "median_rally_pct": 116.46,
      "best_rally_pct": 942.22,
      "worst_rally_pct": 8.23
    },
    "splits": [],
    "split_risk": {
      "split_detected": false,
      "risk_level": "NONE",
      "confidence": "HIGH"
    },
    "data_quality": {
      "price_reliability": "RELIABLE",
      "pnl_reliability": "RELIABLE",
      "overall_confidence": "HIGH"
    },
    "risk_flags": [
      "EXTREME_DRAWDOWN",
      "FREQUENT_CRASHES"
    ],
    "last_updated": "2026-01-29 10:04:56 UTC",
    "volatility": {
      "atr_normalized": 8.0,
      "stddev_20d": 0.5493
    },
    "trends": {
      "intelligence_signal": "DOWNTREND"
    }
  },
  "decision_summary": {
    "why_it_matters": [
      "APEX 61/100 indicates strong opportunity quality",
      "Timing regime: EARLY_BUILD",
      "Historical profile: 3 rallies, 152% best run"
    ],
    "main_risk": "Confidence 45/100 - full data loaded",
    "watch_next": [
      "RNS catalysts (funding/operational updates)",
      "Volume expansion confirmation",
      "Timing regime change signals"
    ]
  },
  "triangulation": {
    "rns": {
      "has_data": true,
      "ticker": "SVNS.L",
      "latest": [
        {
          "title": "Expansion of SVN-015 into depression",
          "date": "28th Jan 2026",
          "announcement_date": "28th Jan 2026",
          "release_time": "7:00 am",
          "source": "RNS",
          "content": "28 Jan 2026 07:00\nRNS Number : 5931Q\nSolvonis Therapeutics PLC\n28 January 2026\nTHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION WILL BE CONSIDERED TO BE IN THE PUBLIC DOMAIN.\n28 January 2026\nSolvonis Therapeutics plc(\"Solvonis\" or the \"Company\")\nExpansion of SVN-015 into depression following positive preclinical data\nDemonstrates antidepressant-like activity benchmarked against fluoxetine (Prozac\u00ae), supporting potential in patients with inadequate SSRI response\nSolvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company developing novel medicines for high-burden central nervous system (\"CNS\") disorders, announces the expansion of its investigational compound SVN-015 into the treatment of\ndepression\n, supported by preclinical data demonstrating antidepressant-like activity benchmarked against fluoxetine.\nKey highlights:\n\u00b7\nSVN-015 expanded into depression following positive preclinical data in validated rodent behavioural models\n\u00b7\nAntidepressant-like activity benchmarked against fluoxetine after 14-day, once-daily dosing\n\u00b7\nSVN-015 is a novel Serotonin-Dopamine Reuptake Inhibitor (\"SDRI\") designed to engage pathways central to mood, motivation and reward processing\n\u00b7\nSupports potential in patients with inadequate response to SSRIs in depression, including symptoms such as anhedonia and reduced motivation\n\u00b7\nSVN-015 is expected to be developed as a once-daily oral therapy suitable for at-home use, aligned with standard antidepressant treatment cycles\nIn a direct preclinical evaluation, SVN-015 demonstrated antidepressant-like activity comparable to fluoxetine following 14-day, once-daily dosing in validated rodent behavioural models widely used to assess antidepressant activity. Fluoxetine, a selective serotonin reuptake inhibitor (\"SSRI\"), is one of the most established benchmark compounds in antidepressant drug development.\nSVN-015 is a novel Serotonin-Dopamine Reuptake Inhibitor (\"SDRI\"), with patent applications filed, designed to engage pathways central to mood regulation, motivation, and reward processing. Despite widespread SSRI use, many patients fail to achieve adequate symptom control, particularly for symptoms such as anhedonia (feeling emotionally flat), reduced motivation, and impaired reward function. According to the U.S. National Institute of Mental Health (NIMH), Major Depressive Disorder (\"MDD\") affects more than 20 million adults in the United States annually, and tens of millions more across major international markets, including Europe and Japan.\nSVN-015 is expected to be developed as a once-daily oral therapy suitable for at-home use, intended to support continuous symptom management within standard antidepressant treatment cycles. Its delivery model and reimbursement pathway are intended to align with established SSRI therapies, with potential advantages in scalability, patient access and long-term adherence.\nAs previously announced, SVN-015 has also been independently selected for evaluation within the U.S. National Institute on Drug Abuse (\"NIDA\") Addiction Treatment Discovery Program for stimulant use disorders, providing external, non-dilutive validation of the compound's pharmacological profile in a separate CNS indication. This programme is separate from Solvonis' research on depression.\nAnthony Tennyson, Chief Executive Officer, commented:\n\"\nDemonstrating antidepressant-like activity versus a gold-standard SSRI following repeat dosing is a notable preclinical signal, supporting SVN-015's expansion into research and development of small molecule therapies for depression.\"\nProfessor David Nutt, Chief Scientific Officer, added:\n\"These data are highly encouraging and reflect a mechanistically grounded approach engaging both serotonergic and dopaminergic systems. Demonstrating antidepressant-like effects under repeat-dose conditions supports further development of SVN-015 and the broader SDRI class as a potential new class of antidepressant medicines.\"\nEnquiries:\nSolvonis Therapeutics plc\nVia Walbrook\nAnthony Tennyson, CEO & Executive Director\nSinger Capital Markets\n(Broker)\n+44 (0) 20 7496 3000\nPhil Davies\nWalbrook PR (PR/IR advisers)\nTel: +44 (0)20 7933 8780 or\nsolvonistherapeutics@walbrookpr.com\nAnna Dunphy\nMob: +44 (0)7876 741 001\nLianne Applegarth\nMob:\n+44 (0)7584 391 303\nRachel Broad\nMob:\u00a0+44 (0)7747 515 393\nAbout Solvonis Therapeutics plc\nSolvonis Therapeutics plc (LSE: SVNS) is an emerging biopharmaceutical company developing novel small-molecule therapeutics for high-burden central nervous system (CNS) disorders. Headquartered in London and listed on the main market of the London Stock Exchange, Solvonis is advancing a differentiated pipeline of repurposed and novel compounds across addiction and psychiatry.\nThe Company's lead programmes address Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD), with additional development and discovery work supporting expansion into further addiction and psychiatric indications, including stimulant use disorder and depressive disorders.\nIts lead asset, SVN-001, is currently in Phase 3 for severe AUD in the UK, while SVN-002 is preparing for a Phase 2b trial in the US targeting moderate-to-severe AUD. The preclinical PTSD programme (SVN-SDN-14) leverages novel serotonin-dopamine modulators designed to enhance pro-social behaviour and long-term outcomes.\nIn parallel, Solvonis is advancing proprietary CNS discovery programmes supported by a dedicated compound library to identify new small-molecule modulators of key neurotransmitter systems. This platform enables efficient early-stage innovation and supports the Company's integrated approach to developing therapies across its three strategic pillars.\nWith a capital-efficient model, dual development strategy, and near-term partnering opportunities, Solvonis is positioned to deliver sustained value through innovation in CNS therapeutics.\nsolvonis.com\n|\nLinkedIn\n|\nX (Twitter)\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nMSCBSGDBGBDDGLR",
          "rns_number": "RNS Number : 5931Q"
        },
        {
          "title": "US Patent allowance for PTSD discovery programme",
          "date": "7th Jan 2026",
          "announcement_date": "7th Jan 2026",
          "release_time": "7:00 am",
          "source": "RNS",
          "content": "7 Jan 2026 07:00\nRNS Number : 8747N\nSolvonis Therapeutics PLC\n07 January 2026\nSolvonis Therapeutics plc\n(\"Solvonis\" or the \"Company\")\nU.S. Patent allowance received for PTSD discovery programme\nDemonstrating scientific and commercial significance\nSolvonis Therapeutics plc (LSE: SVNS\n), an emerging biopharmaceutical company developing novel medicines for high-burden central nervous system (\"CNS\") disorders, announces that it has received a Notice of Allowance (the \"Allowance\") from the United States Patent and Trademark Office (\"USPTO\") for a series of compounds within its proprietary SVN-SDN-14 Post-Traumatic Stress Disorder (\"PTSD\") discovery programme. One compound from this series is currently being evaluated alongside other candidates, with a lead compound expected to be selected in Q1 2026 in line with prior guidance.\nThe Allowance strengthens the intellectual property foundations of SVN-SDN-14 at an important stage as the programme advances toward lead-candidate selection. In addition to this IP milestone, the Company is highlighting the scientific significance of the newly protected compounds in addressing long-standing challenges in the development of next-generation PTSD therapeutics.\nScientific significance\nSVN-SDN-14 is focused on developing serotonin (\"SERT\"), dopamine (\"DAT\") and noradrenaline (\"NET\") modulators designed to support pro-social engagement and improve the effectiveness of psychological therapy in PTSD.\nWhile balanced modulation of these pathways is increasingly recognised as therapeutically valuable, translating this biology into a practical medicine has historically been difficult. Key challenges have included controlling duration of action,\nmanaging variability between patients, and ensuring compatibility with scalable, real-world clinical use.\nThe newly allowed patent covers a novel chemical series designed to retain the core SERT, DAT and NET activity underpinning the programme, while introducing greater pharmacological control through predictable metabolic deactivation. This approach is intended to maintain therapeutic effects while improving dosing flexibility, safety margins and overall suitability for clinical use.\nIn allowing the claims, the USPTO examiner concluded that no existing patents or publications disclosed or suggested the claimed compounds, confirming the novelty of the approach.\nProfessor David Nutt, Chief Scientific Officer of Solvonis, commented:\n\"These compounds are scientifically exciting because they address a long-standing challenge in this field. They are designed to preserve the monoaminergic profile that supports positive social engagement in therapy, while introducing a level of pharmacokinetic control that has historically been difficult to achieve. This increases our confidence that the core biology of SVN-SDN-14 can be translated into a medicine that is practical to develop, regulate and ultimately deploy.\"\nAnthony Tennyson, Chief Executive Officer of Solvonis, added:\n\"This patent allowance strengthens both the scientific and commercial foundations of our PTSD programme. It reflects our strategy of combining rigorous neuroscience with disciplined medicinal chemistry to build differentiated, scalable CNS therapeutics.\"\nEnquiries:\nSolvonis Therapeutics plc\nVia Walbrook\nAnthony Tennyson, CEO & Executive Director\nSinger Capital Markets\n(Broker)\n+44 (0) 20 7496 3000\nPhil Davies\nWalbrook PR (PR/IR advisers)\nTel: +44 (0)20 7933 8780 or\nsolvonistherapeutics@walbrookpr.com\nAnna Dunphy\nMob: +44 (0)7876 741 001\nLianne Applegarth\nMob:\n+44 (0)7584 391 303\nRachel Broad\nMob:\u00a0+44 (0)7747 515 393\nAbout Solvonis Therapeutics plc\nSolvonis Therapeutics plc (LSE: SVNS) is an emerging biopharmaceutical company developing novel small-molecule therapeutics for high-burden central nervous system (CNS) disorders. Headquartered in London and listed on the main market of the London Stock Exchange, Solvonis is advancing a differentiated pipeline of repurposed and novel compounds across addiction, psychiatry, and neurology.\nThe Company's lead programmes address Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD), with additional discovery work supporting expansion into broader CNS indications. Its lead asset, SVN-001, is currently in Phase 3 for severe AUD in the UK, while SVN-002 is preparing for a Phase 2b trial in the US targeting moderate-to-severe AUD. The preclinical PTSD programme (SVN-SDN-14) leverages novel serotonin-dopamine modulators designed to enhance pro-social behaviour and long-term outcomes.\nIn parallel, Solvonis is advancing proprietary CNS discovery programmes built on a dedicated compound library to identify new small-molecule modulators of key neurotransmitter systems. This platform enables efficient early-stage innovation and supports the Company's integrated approach to developing therapies across its three strategic pillars.\nWith a capital-efficient model, dual development strategy, and near-term partnering opportunities, Solvonis is positioned to deliver sustained value through innovation in CNS therapeutics.\nsolvonis.com\n|\nLinkedIn\n|\nX (Twitter)\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nMSCEASFKELSKEFA",
          "rns_number": "RNS Number : 8747N"
        },
        {
          "title": "Research and Development Update - Q4 2025",
          "date": "22nd Dec 2025",
          "announcement_date": "22nd Dec 2025",
          "release_time": "7:00 am",
          "source": "RNS",
          "content": "22 Dec 2025 07:00\nRNS Number : 3621M\nSolvonis Therapeutics PLC\n22 December 2025\n22 December 2025\nSolvonis Therapeutics plc\n(\"Solvonis\" or the \"Company\")\nResearch and Development Update - Q4 2025\nPipeline advancing across addiction and psychiatry with multiple 2026 catalysts\nSolvonis Therapeutics plc (LSE: SVNS),\nan emerging biopharmaceutical company developing novel medicines for high-burden central nervous system (\"CNS\") disorders,\nprovides an update on progress across its development pipeline and discovery programmes as the Company concludes 2025 and enters a catalyst-rich period in 2026.\nPipeline development advancing across addiction and psychiatry\nSVN-001 | Severe Alcohol Use Disorder (AUD) - UK & EU\nThe Company's lead programme, SVN-001, continues to advance through a potentially pivotal Phase 3 clinical trial for severe AUD in the United Kingdom, addressing a large and underserved patient population across the UK and EU. In parallel, the Company continues to progress licensing and commercial-partnership discussions.\nRecruitment remains ongoing in this\nNHS\n-based study, conducted in collaboration with the University of Exeter (\"\nUoE\n\") and co-funded by the National Institute for Health and Care Research (\"\nNIHR\n\"), the Medical Research Council (\"\nMRC\n\"), and Solvonis. Top-line results are anticipated in late 2027 / early 2028. In parallel, with potential partners in UK and internationally.\nSVN-002 | Moderate-to-Severe AUD - Global (ex-UK & EU) | Initial focus: United States\nSVN-002, Solvonis' proprietary esketamine oral thin-film programme, is being advanced under a planned U.S. FDA 505(b)(2) regulatory pathway referencing Johnson & Johnson's blockbuster esketamine product, Spravato\u00ae.\nDuring Q4 2025, preparatory work continued with WuXi AppTec on a pharmacokinetic bridging programme to support regulatory alignment. Initial data are expected in Q1 2026, with further progress through Q2 2026.\nIf the scientific bridge to Spravato\u00ae is successfully established the Company plans to promptly seek approval from the US Food and Drug Administration (\"\nFDA\n\") for a Phase 2b trial, thereby potentially avoiding the significant costs associated with pre-clinical programmes and Phase1 and Phase 2a trials.\nThe programme targets approximately 15 million adults in the United States living with moderate-to-severe AUD and represents a differentiated, clinic-based therapeutic approach within a large and underserved market.\nSVN-015 | Stimulant (Methamphetamine and Cocaine) Use Disorder\nIn December 2025, Solvonis announced that SVN-015, a novel compound emerging from its AI-enabled discovery programme, was accepted into the U.S. National Institute on Drug Abuse's (\"\nNIDA\n\") Addiction Treatment Discovery Program (\"\nATDP\n\").\nUnder the programme, NIDA - part of the U.S. National Institutes of Health (\"\nNIH\n\") - will fund and conduct a standard package of preclinical safety and pharmacology studies, including cardiovascular risk assessment. Initial results are expected in Q1 2026. Subject to supportive outcomes, SVN-015 may progress into further NIDA-funded efficacy testing in validated models of methamphetamine and cocaine addiction.\nAcceptance into ATDP represents an important external validation of Solvonis' proprietary discovery platform and expands the Company's pipeline beyond alcohol use disorder into stimulant addictions, which remain among the most severe psychiatric conditions with no approved pharmacological treatments.\nSuccessful completion of the ATDP programme would position Solvonis to compete for subsequent NIH development funding, including potential UG3/UH3 awards, providing a non-dilutive pathway from preclinical validation toward clinical development.\nSVN-SDN-14 | Post-Traumatic Stress Disorder (PTSD)\nFollowing the announcement of positive preclinical data in August 2025, Solvonis' proprietary serotonin-dopamine-noradrenalin modulator programme continues to progress through final in-vivo studies designed to support lead-candidate selection.\nFour compounds are currently being evaluated in rat brain microdialysis studies to confirm central pharmacokinetics and target engagement across relevant monoaminergic pathways. Lead-candidate selection is expected in Q1 2026, after which the Company intends to advance the selected compound into IND-enabling studies.\nAI-enabled CNS discovery platform\nBeyond SVN-015 and SVN-SDN-14, Solvonis continues to advance its AI-enabled discovery programme, generating novel small-molecule candidates targeting key neurotransmitter systems relevant to addiction and psychiatry. Exploratory work is also underway to assess potential applications in neurology.\nFurther updates on discovery-stage progress are expected during H1 2026 as compound evaluation and prioritisation continue.\nAnthony Tennyson, Chief Executive Officer of Solvonis Therapeutics plc, commented:\n\"\n2025 has been a transformative year for Solvonis. The completion of the acquisition of Awakn Life Sciences in May materially reshaped the Company, establishing a differentiated CNS platform spanning late-stage clinical development, earlier-stage discovery, and multiple regulatory pathways.\n\"Over the course of the year, we have advanced our clinical programmes with discipline, strengthened our balance sheet, and progressed our proprietary discovery capability, including securing external validation through the acceptance of SVN-015 into the U.S. National Institute on Drug Abuse's Addiction Treatment Discovery Program.\n\"As we look ahead to 2026, the Company is entering a period with multiple clearly defined catalysts across regulatory, preclinical, and discovery activities. Our strategy remains centred on capital efficiency, clear regulatory pathways, and partnering optionality, which we believe provides near, medium, and long-term shareholder value creation opportunities.\"\nOutlook\nSolvonis enters 2026 with a diversified CNS pipeline spanning late-stage clinical development, near-term regulatory catalysts, and early-stage discovery programmes supported by external validation and non-dilutive funding pathways.\nThe Company remains focused on disciplined execution across its addiction and psychiatry programmes while continuing to selectively expand its proprietary discovery platform.\nEnquiries:\nSolvonis Therapeutics plc\nVia Walbrook\nAnthony Tennyson, CEO & Executive Director\nSinger Capital Markets\n(Broker)\n+44 (0) 20 7496 3000\nPhil Davies\nWalbrook PR (PR/IR advisers)\nTel: +44 (0)20 7933 8780 or\nsolvonistherapeutics@walbrookpr.com\nAnna Dunphy\nMob: +44 (0)7876 741 001\nLianne Applegarth\nMob:\n+44 (0)7584 391 303\nRachel Broad\nMob:\u00a0+44 (0)7747 515 393\nAbout Solvonis Therapeutics plc\nSolvonis Therapeutics plc (LSE: SVNS) is an emerging biopharmaceutical company developing novel small-molecule therapeutics for high-burden central nervous system (CNS) disorders. Headquartered in London and listed on the main market of the London Stock Exchange, Solvonis is advancing a differentiated pipeline of repurposed and novel compounds across addiction, psychiatry, and neurology.\nThe Company's lead programmes address Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD), with additional discovery work supporting expansion into broader CNS indications. Its lead asset, SVN-001, is currently in Phase 3 for severe AUD in the UK, while SVN-002 is preparing for a Phase 2b trial in the US targeting moderate-to-severe AUD. The preclinical PTSD programme (SVN-SDN-14) leverages novel serotonin-dopamine modulators designed to enhance pro-social behaviour and long-term outcomes.\nIn parallel, Solvonis is advancing proprietary CNS discovery programmes built on a dedicated compound library to identify new small-molecule modulators of key neurotransmitter systems. This platform enables efficient early-stage innovation and supports the Company's integrated approach to developing therapies across its three strategic pillars.\nWith a capital-efficient model, dual development strategy, and near-term partnering opportunities, Solvonis is positioned to deliver sustained value through innovation in CNS therapeutics.\nsolvonis.com\n|\nLinkedIn\n|\nX (Twitter)\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nUPDPKCBBOBDDFBD",
          "rns_number": "RNS Number : 3621M"
        },
        {
          "title": "SVN-015 accepted into US NIDA funded programme",
          "date": "3rd Dec 2025",
          "announcement_date": "3rd Dec 2025",
          "release_time": "7:00 am",
          "source": "RNS",
          "content": "3 Dec 2025 07:00\nRNS Number : 9389J\nSolvonis Therapeutics PLC\n03 December 2025\nSolvonis Therapeutics plc\n(\"Solvonis\" or the \"Company\")\nSolvonis' Novel Compound SVN-015 Accepted into US NIDA-Funded Addiction Treatment Discovery Program for Methamphetamine and Cocaine Addiction\nSolvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company developing novel medicines for high-burden central nervous system (CNS) disorders, announces that its novel AI-discovered compound, SVN-015, targeting methamphetamine and cocaine use disorders, has been accepted into the US National Institute on Drug Abuse's (\"NIDA\") Addiction Treatment Discovery Program (\"ATDP\"). Under the programme, NIDA, part of the US National Institutes of Health (\"NIH\"), will fund and conduct early preclinical evaluation of SVN-015.\nProgramme Overview\nIn the first stage of the programme, NIDA will fund and carry out\nin vitro\npredictive safety studies on SVN-015 to assess potential cardiovascular risks. These tests are the normal first step in the development of any new medicine. If the results are supportive, SVN-015 could advance into ATDP efficacy studies in validated preclinical models of methamphetamine and cocaine addiction.\nIf the efficacy studies are successful, Solvonis would be well positioned to compete for a non-dilutive NIH research grant, which can provide up to US$3 million per year for as long as five years. These grants are competitive, but completion of early preclinical studies would provide the type of safety and efficacy data needed to support Solvonis' grant application. This creates a potential pathway from funded NIDA preclinical work through to potential NIH-funded clinical trials in humans.\nStrategic Significance\nAcceptance of SVN-015 into the ATDP marks an important milestone for Solvonis as it expands the Company's research in addiction beyond alcohol use disorder (\"AUD\") into stimulant addictions - specifically methamphetamine and cocaine - which remain among the most severe psychiatric conditions with no approved drug treatments.\nProfessor David Nutt, Solvonis Chief Scientific Officer, commented\n\"Being accepted into NIDA's ATDP for SVN-015 is a major step forward for Solvonis. ATDP provides a pathway for evaluating the therapeutic potential of SVN-015, starting with early preclinical testing and, if successful, creating the opportunity to progress towards NIH clinical development funding through the UG3/UH3 programme. For methamphetamine and cocaine addiction - where no approved drug treatments exist - this represents an important advance.\"\nEnquiries:\nSolvonis Therapeutics plc\nVia Walbrook\nAnthony Tennyson, CEO & Executive Director\nSinger Capital Markets\n(Broker)\n+44 (0) 20 7496 3000\nPhil Davies\nWalbrook PR (PR/IR advisers)\nTel: +44 (0)20 7933 8780 or\nsolvonistherapeutics@walbrookpr.com\nAnna Dunphy\nMob: +44 (0)7876 741 001\nLianne Applegarth\nMob:\n+44 (0)7584 391 303\nMarcus Ulker\nMob:\u00a0+44 (0)7867 984 082\nAbout SVN-015\nSVN-015 is the second compound emerging from Solvonis' AI-enabled drug discovery programme to progress into external validation, following the advancement of SVN-SDN-14 for Post-Traumatic Stress Disorder. It is a novel candidate designed to address stimulant addictions - including methamphetamine and cocaine dependence - areas with significant unmet need and no currently approved pharmacological treatments.\nAbout NIDA\nThe US National Institute on Drug Abuse (\"NIDA\") is a component of the National Institutes of Health, U.S. Department of Health and Human Services. NIDA supports most of the world's research on the health aspects of drug use and addiction. The Institute carries out a large variety of programs to inform policy, improve practice, and advance addiction science.\nAbout Methamphetamine and Cocaine Addiction\nMethamphetamine and cocaine addiction remain major public health challenges. There are no approved pharmacological treatments; patients are managed only with psychosocial interventions, which deliver limited and inconsistent outcomes. Both NIDA and the European Monitoring Centre for Drugs and Drug Addiction (\"EMCDDA\") identify stimulant use disorders as areas of critical unmet need, associated with high morbidity, mortality, and significant societal costs.\nEpidemiological data highlights the scale of the problem. In the United States, the National Survey on Drug Use and Health (\"SAMHSA 2022\") estimates approximately 2.6 million people meet diagnostic criteria for cocaine or methamphetamine use disorders. In the EU5, EMCDDA data indicate 0.35-0.5 million patients, predominantly with cocaine dependence. In Japan, national data suggest around 0.1 million patients, largely with methamphetamine dependence. Taken together, this represents a combined total of around 3.0-3.2 million individuals across the seven major markets - a large population with no existing drug treatment options.\nThe content of this press release is solely the responsibility of Solvonis and does not necessarily represent the official views of the National Institutes of Health.\nAbout Solvonis Therapeutics plc\nSolvonis Therapeutics plc (LSE: SVNS) is an emerging biopharmaceutical company developing novel small-molecule therapeutics for high-burden central nervous system (CNS) disorders. Headquartered in London and listed on the main market of the London Stock Exchange, Solvonis is advancing a differentiated pipeline of repurposed and novel compounds across addiction, psychiatry, and neurology.\nThe Company's lead programmes address Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD), with additional discovery work supporting expansion into broader CNS indications. Its lead asset, SVN-001, is currently in Phase 3 for severe AUD in the UK, while SVN-002 is preparing for a Phase 2b trial in the US targeting moderate-to-severe AUD. The preclinical PTSD programme (SVN-SDN-14) leverages novel serotonin-dopamine modulators designed to enhance pro-social behaviour and long-term outcomes.\nIn parallel, Solvonis is advancing proprietary CNS discovery programmes built on a dedicated compound library to identify new small-molecule modulators of key neurotransmitter systems. This platform enables efficient early-stage innovation and supports the Company's integrated approach to developing therapies across its three strategic pillars.\nsolvonis.com\n|\nLinkedIn\n|\nX (Twitter)\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nMSCBUBDDXBGDGUD",
          "rns_number": "RNS Number : 9389J"
        },
        {
          "title": "Total Voting Rights",
          "date": "31st Oct 2025",
          "announcement_date": "31st Oct 2025",
          "release_time": "3:59 pm",
          "source": "RNS",
          "content": "31 Oct 2025 15:59\nRNS Number : 7597F\nSolvonis Therapeutics PLC\n31 October 2025\n31 October 2025\nSolvonis Therapeutics plc\n(\"Solvonis\" or the \"Company\")\nTotal Voting Rights\nSolvonis Therapeutics plc (LSE: SVNS),\nan emerging biopharmaceutical company developing novel medicines for high-burden central nervous system (\"CNS\") disorders, confirms that the Company's issued share capital as at the date of this announcement comprises 6,806,403,493 Ordinary Shares with one voting right each. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of Ordinary Shares and voting rights in the Company is 6,806,403,493.\nThis includes an amendment to the issue of shares announced on 31 October 2025 where the correct figure to be issued and admitted is 23,636,362. The original figure announced was 26,636,362.\nThe above figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company.\nEnquiries:\nSolvonis Therapeutics plc\nanthony@solvonis.com\nAnthony Tennyson, CEO & Executive Director\nSinger Capital Markets (Corporate Broker)\nPhil Davies +44 (0) 20 7496 3000\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nTVREASEFDSPSFFA",
          "rns_number": "RNS Number : 7597F"
        }
      ],
      "themes": [
        "operations"
      ]
    },
    "social": {
      "has_data": true,
      "buzz_level": "HIGH",
      "post_count": 425,
      "sentiment_breakdown": {
        "positive": 0.0,
        "neutral": 100.0,
        "negative": 0.0
      }
    },
    "trends": {
      "has_data": true,
      "current_interest": 0,
      "momentum_score": 0,
      "trend_direction": "flat",
      "intelligence_signal": "DOWNTREND"
    },
    "volatility": {
      "atr_normalized": 8.0,
      "stddev_20d": 0.5493
    },
    "risk_flags": {
      "split_risk_level": "NONE",
      "halt_risk": "NONE",
      "penny_stock_risk": "NONE"
    },
    "catalyst_dates": {
      "proxy_date": "2025-10-07"
    }
  },
  "ai_insights": {
    "key_insights": [],
    "hidden_patterns": [],
    "contrarian_signals": [],
    "risk_warnings": [],
    "opportunity_flags": [],
    "narrative_summary": "ERROR presents a standard crash recovery setup without unusual patterns detected. Monitor for catalyst developments and trend shifts.",
    "_selected_rns": [
      {
        "title": "Expansion of SVN-015 into depression",
        "date": "2026-01-28T00:00:00",
        "importance_score": 0.7979351032448376,
        "time_bucket": "NEAR",
        "rns_number": ""
      },
      {
        "title": "Research and Development Update - Q4 2025",
        "date": "2025-12-22T00:00:00",
        "importance_score": 0.7215339233038347,
        "time_bucket": "MID",
        "rns_number": ""
      },
      {
        "title": "US Patent allowance for PTSD discovery programme",
        "date": "2026-01-07T00:00:00",
        "importance_score": 0.7045722713864306,
        "time_bucket": "NEAR",
        "rns_number": ""
      },
      {
        "title": "SVN-015 accepted into US NIDA funded programme",
        "date": "2025-12-03T00:00:00",
        "importance_score": 0.6823008849557521,
        "time_bucket": "MID",
        "rns_number": ""
      },
      {
        "title": "Raises \u00a31.25 Million to Accelerate Programmes",
        "date": "2025-10-16T00:00:00",
        "importance_score": 0.5831858407079645,
        "time_bucket": "MID",
        "rns_number": ""
      },
      {
        "title": "Total Voting Rights",
        "date": "2025-10-31T00:00:00",
        "importance_score": 0.5641592920353983,
        "time_bucket": "MID",
        "rns_number": ""
      },
      {
        "title": "Corporate Structure Update and Issue of Options",
        "date": "2025-10-31T00:00:00",
        "importance_score": 0.5641592920353983,
        "time_bucket": "MID",
        "rns_number": ""
      },
      {
        "title": "Appoints global biopharma leader Paul Carter",
        "date": "2025-10-27T00:00:00",
        "importance_score": 0.5558997050147493,
        "time_bucket": "MID",
        "rns_number": ""
      },
      {
        "title": "SVN-SDN-14 PTSD - Positive pre-clinical results",
        "date": "2025-08-12T00:00:00",
        "importance_score": 0.5489675516224188,
        "time_bucket": "MID",
        "rns_number": ""
      },
      {
        "title": "Half-year Report",
        "date": "2025-09-30T00:00:00",
        "importance_score": 0.5001474926253687,
        "time_bucket": "MID",
        "rns_number": ""
      },
      {
        "title": "AGM Statement",
        "date": "2025-06-27T00:00:00",
        "importance_score": 0.44287118977384465,
        "time_bucket": "LONG",
        "rns_number": ""
      },
      {
        "title": "Solvonis secures exclusive CNS collaboration",
        "date": "2025-08-28T00:00:00",
        "importance_score": 0.43200589970501474,
        "time_bucket": "MID",
        "rns_number": ""
      },
      {
        "title": "Media Coverage: Small Cap Idea profile",
        "date": "2025-08-13T00:00:00",
        "importance_score": 0.40103244837758106,
        "time_bucket": "MID",
        "rns_number": ""
      },
      {
        "title": "\u00a31m subscription to accelerate AI drug discovery",
        "date": "2025-07-11T00:00:00",
        "importance_score": 0.3828908554572271,
        "time_bucket": "LONG",
        "rns_number": ""
      },
      {
        "title": "Completion of the acquisition of Awakn",
        "date": "2025-05-28T00:00:00",
        "importance_score": 0.3809242871189773,
        "time_bucket": "LONG",
        "rns_number": ""
      },
      {
        "title": "Result of placing",
        "date": "2025-05-16T00:00:00",
        "importance_score": 0.3561455260570304,
        "time_bucket": "LONG",
        "rns_number": ""
      },
      {
        "title": "Translational Bridging Studies",
        "date": "2025-07-22T00:00:00",
        "importance_score": 0.3556047197640118,
        "time_bucket": "LONG",
        "rns_number": ""
      },
      {
        "title": "Proposed equity fundraising via ABB",
        "date": "2025-05-15T00:00:00",
        "importance_score": 0.35408062930186823,
        "time_bucket": "LONG",
        "rns_number": ""
      },
      {
        "title": "Exercise of warrants",
        "date": "2025-07-18T00:00:00",
        "importance_score": 0.3473451327433628,
        "time_bucket": "LONG",
        "rns_number": ""
      },
      {
        "title": "Solvonis Chair to speak at Lucid Capital Markets",
        "date": "2025-07-14T00:00:00",
        "importance_score": 0.3390855457227139,
        "time_bucket": "LONG",
        "rns_number": ""
      }
    ]
  },
  "crashdash": {
    "industry_intelligence": {
      "category": "INDUSTRIALS",
      "name": "Industrials",
      "icon": "\ud83c\udfed",
      "color": "#64748b",
      "crash_patterns": [
        "Order book decline or cancellations",
        "Margin compression (input costs)",
        "Cyclical demand weakness",
        "Project delays or overruns",
        "Working capital strain"
      ],
      "recovery_paths": [
        "Order book growth or new contracts",
        "Margin recovery (efficiency gains)",
        "Cyclical upturn (capex recovery)",
        "M&A consolidation",
        "Product innovation or new markets"
      ],
      "active_patterns": [
        "Project delays or overruns"
      ],
      "relevant_rns_count": 0,
      "key_metrics": [
        "Order book value (forward revenue)",
        "Book-to-bill ratio",
        "Operating margin trends",
        "Working capital efficiency",
        "Capex cycles (customer industries)"
      ]
    },
    "panic_analysis": {
      "panic_score": 50.5,
      "signal": "MODERATE_FEAR",
      "interpretation": "\ud83d\udfe1 Cautious sentiment - assess risk/reward",
      "breakdown": {
        "price_destruction": 28.5,
        "volume_death": 14,
        "social_silence": 6,
        "news_sentiment": 2
      },
      "is_opportunity": false,
      "opportunity_reason": "\ud83d\udcca Moderate fear detected - monitor for escalation"
    },
    "fear_vs_facts": {
      "fear_points": [
        "\ud83d\udc94 Price destruction: 28/40 points"
      ],
      "facts_points": [
        "\ud83d\udcc8 Historical upside: 152% proven capacity"
      ],
      "verdict": "\u2696\ufe0f Mixed signals - Fear and facts balanced, wait for clarity"
    },
    "crashhunter_signals": [
      {
        "type": "BUILDING",
        "icon": "\ud83d\udcca",
        "text": "Building",
        "color": "#10b981"
      },
      {
        "type": "MODERATE_QUALITY",
        "icon": "\ud83c\udf1f",
        "text": "APEX 61",
        "color": "#3b82f6"
      }
    ],
    "catalyst_pipeline": [
      {
        "type": "rns",
        "date": "28th Jan 2026",
        "title": "Expansion of SVN-015 into depression",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "7th Jan 2026",
        "title": "US Patent allowance for PTSD discovery programme",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "22nd Dec 2025",
        "title": "Research and Development Update - Q4 2025",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "3rd Dec 2025",
        "title": "SVN-015 accepted into US NIDA funded programme",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "rns",
        "date": "31st Oct 2025",
        "title": "Total Voting Rights",
        "status": "published",
        "icon": "\ud83d\udce2"
      },
      {
        "type": "expected",
        "date": "Expected soon",
        "title": "Watch for: Funding announcement or operational update",
        "status": "pending",
        "icon": "\ud83d\udd2e"
      },
      {
        "type": "expected",
        "date": "Expected soon",
        "title": "Watch for: Volume expansion confirmation",
        "status": "pending",
        "icon": "\ud83d\udd2e"
      }
    ],
    "decision_matrix": {
      "decision": "WATCH",
      "reason": "\u23f3 Monitor for timing regime change or panic escalation",
      "checklist": [
        {
          "criterion": "Panic Score",
          "value": "50/100",
          "pass": false,
          "icon": "\ud83d\udfe2"
        },
        {
          "criterion": "Timing Regime",
          "value": "EARLY_BUILD",
          "pass": true,
          "icon": "\u2705"
        },
        {
          "criterion": "APEX Quality",
          "value": "61/100",
          "pass": true,
          "icon": "\u2b50"
        },
        {
          "criterion": "Data Confidence",
          "value": "45/100",
          "pass": true,
          "icon": "\ud83c\udfaf"
        },
        {
          "criterion": "Industry Pattern",
          "value": "1 active",
          "pass": true,
          "icon": "\ud83c\udfed"
        }
      ],
      "pass_rate": "4/5"
    },
    "contrarian_panic": {
      "total_score": 32,
      "band": "\ud83d\udfe2 MILD COMPRESSION (Top 50% - WATCHLIST)",
      "components": {
        "compression": {
          "score": 3,
          "max": 40,
          "signals_30d": 1,
          "signals_60d": 1,
          "signals_90d": 1,
          "signals_per_week": 0.08,
          "total_signals": 31,
          "rsi_extreme_count": 0,
          "rsi_ultra_count": 0,
          "escalation_count": 0,
          "density_score": 3,
          "rsi_score": 0,
          "escalation_score": 0,
          "description": "0.1 signals/week | Early stage"
        },
        "intensification": {
          "score": 10,
          "max": 20,
          "recent_types": [
            "CRASH ZONE BOTTOM",
            "CRASH ZONE BOTTOM",
            "DEEP CRASH BOTTOM"
          ],
          "escalating": true,
          "sustained": false,
          "current_intensity": 2,
          "pattern": "ESCALATING - Getting worse"
        },
        "volume_death": {
          "score": 5,
          "max": 15,
          "relative_volume": 2.03,
          "description": "Elevated volume - Some activity"
        },
        "pop_potential": {
          "score": 14,
          "max": 15,
          "best_historical_rally": 648.2,
          "avg_rally": 128.7,
          "signal_count": 31,
          "description": "BIG POPPER - Historical 5x+ (648%)"
        },
        "accumulation": {
          "score": 0,
          "max": 10,
          "has_accumulation": false,
          "bars_since_accum": 0,
          "description": "No accumulation"
        }
      },
      "ticker": "SVNS.L",
      "signal_date": "2025-03-10",
      "total_signals_history": 31
    }
  },
  "scoring_breakdown": {
    "apex_factors": [
      "Technical quality: +15 (AI_Technical_Score=12.0/20)",
      "Drawdown reversion potential: +18 (Drawdown_Pct=89.0%)",
      "Volume confirmation: +10 (Relative_Volume=2.0)",
      "Pattern reliability: +10 (Rally_Count=3.0)",
      "Upside history: +8 (best_rally_pct=152%)"
    ],
    "technical_score": {
      "points": 15,
      "ai_score": 12.0,
      "reason": "AI Technical Score 12.0/20 translates to 15/25 points"
    },
    "drawdown_score": {
      "points": 18,
      "drawdown_pct": 88.98,
      "reason": "Drawdown of 89.0% gives 18/20 points"
    },
    "volume_score": {
      "points": 10,
      "rel_volume": 2.03,
      "reason": "Relative volume 2.03x gives 10 points"
    },
    "pattern_score": {
      "points": 10,
      "rally_count": 3.0,
      "reason": "3.0 historical rallies gives 10/15 points"
    },
    "upside_score": {
      "points": 8,
      "best_rally_pct": 151.61,
      "reason": "Best rally of 152% gives 8/20 points"
    },
    "penalties": {
      "total": 0,
      "items": []
    }
  },
  "reasons_buy_sell": {
    "reasons_to_buy": [
      {
        "reason": "Early stage positioning offers best R:R if catalysts appear",
        "tag": "MED",
        "evidence": [
          "timing_regime=EARLY_BUILD",
          "current_return_pct=76.8%"
        ]
      },
      {
        "reason": "Proven winner - previously hit lock-in target",
        "tag": "MED",
        "evidence": [
          "lock_in_reached=True"
        ]
      }
    ],
    "reasons_to_sell": [
      {
        "reason": "Stale signal - not for active trading",
        "tag": "HIGH",
        "evidence": [
          "status=historical",
          "signal_date=2025-03-10"
        ]
      }
    ]
  },
  "trade_plan": {
    "trader_plan": {
      "style": "Watch / Starter",
      "action": "Wait for base + catalyst confirmation; starter position only",
      "sizing": "0-1% until CONFIRMED",
      "risk": "Invalidation = breaks recent lows / dilution / suspension",
      "profit_taking": "Scale out 25% at +15%, 25% at +50%, runner above"
    },
    "investor_plan": {
      "allowed": false,
      "thesis_conditions": "Unlock after AI triangulation + CONFIRMED timing",
      "hold_window": "N/A",
      "risk_management": "N/A"
    }
  },
  "exhaustion": {
    "regime": "EARLY_BUILD",
    "run_multiple": 0.51,
    "current_run_pct": 76.77,
    "avg_historical_run_pct": 151.61
  },
  "history_snapshot": {
    "previous_report_date": null,
    "score_change": null,
    "confidence_change": null,
    "new_events_count": 0,
    "new_rns_titles": []
  },
  "commentary": {
    "executive_summary": "Note: this report used historical signals only \u2014 live triangulation (RNS, social, Trends) was not available. Current setup looks like EARLY_BUILD with an APEX score of 61/100. Historically there have been 3 rallies (avg. 152%); the position is now +76.8%. Practical take: this is interesting but unconfirmed \u2014 wait for an AI snapshot or clear confirmation before committing size.",
    "bull_case": [
      "Early accumulation \u2014 good risk/reward if it confirms"
    ],
    "bear_case": [
      "No immediate red flags, but keep stops tight"
    ],
    "timing_translation": "Accumulation in progress. Consider small starters but wait for confirmation before sizing up.",
    "confidence_explained": "Confidence 45/100 \u2014 data triangulated from RNS, social and Trends."
  },
  "data_quality": {
    "sources_present": {
      "snapshot_json": false,
      "daily_enrichment_row": true,
      "historical_profile": true,
      "metadata": true,
      "triangulation_events": true,
      "ai_insights": true
    },
    "missing_data": [
      "AI insights from Groq LLM"
    ],
    "confidence_impact": "HIGH",
    "disclaimer": "Data provided as-is. Not financial advice. AIM micro-caps carry significant volatility risk."
  }
}